000			02314 a2200697 4500
005			20250517230157.0
264		0	_c20190531
008			201905s 0 0 eng d
022			_a2213-2619
024	7		_a10.1016/S2213-2600(18)30264-9 _2doi
040			_aNLM _beng _cNLM
100	1		_aWang, Zhijie
245	0	0	_aDetection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. _h[electronic resource]
260			_bThe Lancet. Respiratory medicine _c09 2018
300			_a681-690 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAdministration, Oral
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aBiomarkers, Tumor _xblood
650	0	4	_aCirculating Tumor DNA _xblood
650	0	4	_aDNA Mutational Analysis _xmethods
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aGefitinib _xadministration & dosage
650	0	4	_aGenes, Tumor Suppressor
650	0	4	_aGenes, erbB-1
650	0	4	_aHumans
650	0	4	_aIntention to Treat Analysis
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMutation
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aSensitivity and Specificity
700	1		_aCheng, Ying
700	1		_aAn, Tongtong
700	1		_aGao, Hongjun
700	1		_aWang, Kai
700	1		_aZhou, Qing
700	1		_aHu, Yanping
700	1		_aSong, Yong
700	1		_aDing, Cuimin
700	1		_aPeng, Feng
700	1		_aLiang, Li
700	1		_aHu, Yi
700	1		_aHuang, Cheng
700	1		_aZhou, Caicun
700	1		_aShi, Yuankai
700	1		_aZhang, Li
700	1		_aYe, Xin
700	1		_aZhang, Meizhuo
700	1		_aChuai, Shaokun
700	1		_aZhu, Guanshan
700	1		_aHu, Jin
700	1		_aWu, Yi-Long
700	1		_aWang, Jie
773	0		_tThe Lancet. Respiratory medicine _gvol. 6 _gno. 9 _gp. 681-690
856	4	0	_uhttps://doi.org/10.1016/S2213-2600(18)30264-9 _zAvailable from publisher's website
999			_c28642045 _d28642045